Refer to the recommended dosing and administration information for each indication when prescribing ELIQUIS® to patients. See Indications and Important Safety Information, including Boxed WARNINGS.

ELIQUIS® is a prescription medicine used to prevent and treat blood clots in various conditions. Learn about its benefits, risks, dosing, and safety information.

Recommended dosing For all indications: Please see pages 22-23 for additional dosage adjustment information on coadministration with combined P-glycoprotein (P-gp) and cytochrome P450 3A4 (CYP3A4) inhibitors.

• Increased Risk of Thrombotic Events after Premature Discontinuation: Premature discontinuation of any oral anticoagulant, including ELIQUIS, in the absence of adequate alternative anticoagulation increases the risk of thrombotic events. An increased rate of stroke was observed during the transition from ELIQUIS to warfarin in clinical trials in atrial fibrillation …

Learn about Rx ELIQUIS® for stroke risk reduction in NVAF patients and for the treatment of DVT/PE. See Indications and Important Safety Information, including Boxed WARNINGS.

If you are visiting from one of the countries below, please click on the respective flag to access your local country website:

Request ELIQUIS® samples and explore select resources, including savings offers, starter guides, and more. See Indications and Important Safety Information, including Boxed WARNINGS.

Explore the efficacy and safety data for ELIQUIS® in helping to reduce stroke risk in NVAF and for the treatment of DVT/PE. See Indications and Important Safety Information, including Boxed WARNINGS.

Refer to the recommended dosing and administration information for the treatment of DVT/PE when prescribing ELIQUIS® to appropriate patients. See Indications and Important Safety Information, including Boxed WARNINGS.

Review the efficacy and safety data for the prophylaxis of DVT, which may lead to PE, after hip/knee replacement surgery. See Indications and Important Safety Information, including Boxed WARNINGS.